Advertisement

Verapamil Injection

[01 July 2014]

Products Affected - Description

Verapamil Injection, 2.5 mg/mL, Hospira
2 mL ampule (NDC 00409-4011-01)
2 mL vial (NDC 00409-1144-05)
4 mL vial (NDC 00409-1144-02)

Reason for the Shortage

  • Hospira states the shortage was due to manufacturing delays.
  • Hospira is the sole supplier if verapamil injection.

Available Products

Verapamil Injection, 2.5 mg/mL, Hospira
4 mL Ansyr syringe (NDC 00409-9633-05)

Estimated Resupply Dates

Hospira has verapamil 2.5 mg/mL 2 mL ampules and 2 mL vials available in limited supply. The 4 mL vials are on back order and the company estimates a release date of 4th quarter 2014.

Related Shortages

Updated

July 1, 2014; June 10, 2014, University of Utah, Drug Information Service. Copyright 2014, Drug Information Service, University of Utah, Salt Lake City, UT.

Disclaimer

This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.

« Back to Drug Shortage Product Bulletins

Advocacy Activity
Get the latest updates on ASHP's advocacy activity on drug shortages.
Advertisement